00:00It's Benzinga, bringing Wall Street to Main Street.
00:02The U.S. Food and Drug Administration is requiring new safety warnings on all GLP-1 drugs
00:08over a potential increased risk of a rare eye condition that can cause permanent vision loss,
00:14according to CNBC. The condition, known as non-arteritic anterior ischemic optic neuropathy,
00:21or NAION, has been reported for all marketed GLP-1 products,
00:26though a causal relationship has not been established.
00:30An FDA review of 126 clinical trials involving more than 134,000 patients
00:36found 6.4 cases per 100,000 patient years among GLP-1 users, compared with 3.8 among other patients.
00:45Ozempic and Wegovi maker Novo Nordisk said the data do not establish a causal relationship
00:51and expressed confidence in the benefit-risk profile of its GLP-1 drugs.
00:55CNBC contacted Munjaro, ZepBound, and Foundio maker Eli Lilly for comment.
01:02City analysts expect the warnings to have limited impact on GLP-1 uptake,
01:07citing the condition's rarity and the drug's benefits.
01:09For all things money, visit Benzinga.com.
